Investor Presentaiton

6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth ' ibnsinapharma FY19 Net Revenues *** FY19 Gross Profit EGP 16.6 BN Sinapharm EGP 1.4 BN FY19 EBITDA EGP 750.2 MN ▲ 24.6% y-o-y FY19 Net Profit ibnsinapharma EGP 328.8 MN ▲ 35.2% y-o-y ▲ 28.0% y-o-y Source: Company Management ibnsinapharma ▲ 25.2% y-o-y 19

View entire presentation